艾伯維公司 ABBV 深 滬
等待開盤 02-05 09:30:00 美东时间
211.17
-14.490
-6.42%
華盛通- 最 高212.08
- 今 開210.30
- 成交量 646.12万股
- 最 低 204.27
- 昨 收 225.66
- 總市值 3731.37亿
- 52周最高 241.44
- 市盈率 靜 88.34
- 換手率 0.00%
- 52周最低 157.74
- 委 比 -48.72%
- 總股本 17.67亿
- 歷史最高 241.44
- 量 比 2.02
- 振 幅 3.46%
- 歷史最低 -18.61
- 每 手 1
- 風險率 19.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
AbbVie beat Q4 earnings and sales estimates, driven by strong Skyrizi and Rinvoq growth. The drugmaker raised its 2026 outlook despite falling Humira sales and mixed results in aesthetics.
15分钟前
AbbVie shares are trading lower. The company reported Q4 financial results.
AbbVie shares are trading lower. The company reported Q4 financial results.
02-04 22:04
美股机会日报 | 美国1月“小非农”不及预期！礼来绩后一度大涨10%，财报强劲超预期
“小非农”不及预期！美国1月仅新增2.2万个就业岗位；美联储“新主席”生变？民主党人阻挠沃什获提名；礼来绩后一度大涨10%，财报强劲超预期；黄金强势反弹至5000美元上方>>
02-04 22:18
AbbVie Sees FY2026 Adj EPS $14.37-$14.57 vs $14.24 Est
AbbVie (NYSE:ABBV) is looking for FY2026 Adj EPS of $14.37-$14.57 vs $14.24 analyst estimate..
02-04 20:50
AbbVie Q4 Adj. EPS $2.71 Beats $2.65 Estimate, Sales $16.618B Beat $16.421B Estimate
AbbVie (NYSE:ABBV) reported quarterly earnings of $2.71 per share which beat the analyst consensus estimate of $2.65 by 2.19 percent. This is a 25.46 percent increase over earnings of $2.16 per share from the same period
02-04 20:49
Earnings Scheduled For February 4, 2026
Companies Reporting Before The Bell • Oaktree Specialty Lending (NASDAQ:OCSL) i...
02-04 19:11
华盛早报 | 辟谣！税收传闻不实；“AI抢饭碗”引抛售潮！纳指跌近1.5%；黄金、白银暴力反弹，华尔街坚定看多
辟谣！税收传闻不实；“AI抢饭碗”引抛售潮！纳指跌近1.5%；黄金、白银暴力反弹，华尔街坚定看多；AMD最新指引不够炸裂，盘后大跌8%>>
02-04 08:17
A Preview Of AbbVie's Earnings
AbbVie (NYSE:ABBV) is gearing up to announce its quarterly earnings on Wednesda...
02-03 23:01
BRIEF-AbbVie Files FDA, EMA Applications For Rinvoq (Upadacitinib) For Adults, Teens With Vitiligo
BRIEF-AbbVie Files FDA, EMA Applications For Rinvoq (Upadacitinib) For Adults, Teens With Vitiligo Feb 3 (Reuters) - Abbvie Inc ABBV.N : ABBVIE SUBMITS REGULATORY APPLICATIONS TO FDA AND EMA FOR UPADACITINIB (RINVOQ®) IN ADULTS AND ADOLESCENTS WITH VITILIGO Source text: ID:nPn8D2BXla Further company
02-03 21:04
先声药业(02096.HK)进一步收到来自AbbVie支付的4000万美元款项
【财华社讯】先声药业(02096.HK)公布，集团附属公司已与AbbVie附属公司就研究性新候选药物SIM0500订立海外许可选择权协议。根据该协议条款，集团将...
02-03 17:30
